Skip to content

Uncommon Therapeutics

YC W25 · Active · A Disease Focused Biotech, Building Multiple Billion Dollar Drugs

Competitors

Adjacent

Also from W25

All of W25

About Uncommon Therapeutics

Our founder Noah, an experienced tech entrepreneur, was directly impacted by a severe genetic disease when his daughter was diagnosed with Rett Syndrome, a disease that afflicts 1 in 10,000 girls. Using an innovative polytherapy strategy, we’ve successfully improved her quality of life, and have designed new therapeutics that each could be worth billions and together could deliver a cure.

YC batch
W25 · Winter 2025
Status, per YC
Active
Category
Other
Team size
2
Location
San Francisco, CA, USA
Checked
36m ago

YC tags: Gene Therapy, CRISPR, Biotechnology

Uncommon Therapeutics in W25: 165 companies, 83% AI

Uncommon Therapeutics: questions

Which YC batch was Uncommon Therapeutics in?

Uncommon Therapeutics was in Y Combinator's Winter 2025 batch (W25).

Is Uncommon Therapeutics still active?

Y Combinator lists Uncommon Therapeutics as active.

Where is Uncommon Therapeutics based?

Uncommon Therapeutics lists San Francisco, CA, USA as its location on YC's directory.

Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.

New startups by email

Mondays: new YC data, AI and devtools companies and status changes, only when something changed.

Double opt-in. Unsubscribe any time.